Management of Myelofibrosis: from Diagnosis to New Target Therapies.

Abstract excerpt

OPINION STATEMENT: Myelofibrosis (MF) is a clonal disorder of the pluripotent hematopoietic stem cell, whose clinical manifestations can be extremely heterogeneous, including cytopenias, organomegaly, constitutional symptoms, and cachexia. Median survival ranges from approximately 3.5 to 5.5 years; while the most frequent cause of death is the evolution to acute myeloid leukemia, also other conditions such as...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Clinical Decision-Making
• Share to Combined Modality Therapy
• Share to Disease Management